Navigation Links
Transgenomic, Inc. Reports First Quarter 2009 Results

OMAHA, Neb., May 13 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced financial results for the first quarter ended March 31, 2009. The Company's financial results are presented in the tables that follow.

The Company reported a net loss of $953,000 or $.02 per share for the first quarter of 2009 as compared to a net income of $122,000 or $0.00 per share for the first quarter of 2008.

Net sales from continuing operations were $5.0 million during the first quarter 2009, compared to $6.3 million during the comparable period of 2008. Gross profit from continuing operations was $2.8 million or 56 percent during the first quarter of 2009 compared to $3.6 million or 58 percent during the comparable period of 2008. Operating expenses from continuing operations were $3.8 million during the first quarter of 2009 compared to $3.5 million during the same period of 2008. Excluding the impact of foreign currency revaluation gains/losses, operating expenses were down by $0.1 million in the first quarter of 2009 compared to the same period of 2008. Cash and cash equivalents totaled $4.8 million at March 31, 2009.

Comment and Outlook

Craig Tuttle, the Company's President and Chief Executive Officer, noted "Unfortunately, like many companies today, we are also experiencing an impact from the overall economic slowdown. This resulted in a decline in first quarter revenue to $5.0 million compared to our first quarter revenues in 2008 of $6.3 million and a net loss of $1.0 million in the quarter. This decline was primarily the result of a slowdown in instrument orders compared to what we experienced throughout 2008. Our Molecular Diagnostics Laboratory grew from $.9 million to $1.0 million in revenue in the first quarter of 2009 compared to the fourth quarter of 2008. The Molecular Diagnostics Laboratory grew by $447,000 over the first quarter of 2008. We have added an additional 24 new ordering institutions during the first quarter of 2009. This business was also impacted by the current economy which slowed our quarterly growth rates. We believe this is the result of potential patients delaying diagnostic testing during the current economic tumult since we are performing testing for 64 more customers than in the first quarter of 2008. In addition, we do have some customers whose volumes are lower compared to the same period of the prior year. On a positive note, we are beginning to see signs of improved instrument sales for the second quarter."

Earnings Call

Company management will discuss first quarter 2009 financial results via teleconference on Wednesday, May 13, 2009 at 5:00 p.m. Eastern Time. To access the call via telephone, dial 800-895-0231 or 785-424-1054. The Company will also host a live broadcast of the call over the Internet. To listen to the webcast, investors should log on to the Company's Investor Relations web page at and follow the instructions provided. An archived recording of the conference call will be available and can be accessed via the web using the same link listed above for 14 days after the call. Investors can also listen to a replay via telephone until 11:59 p.m. Eastern Time on Wednesday, May 27, 2009. Simply dial 800-723-0544 or 402-220-2656 from any telephone.

About Transgenomic

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, Transgenomic Molecular Clinical Reference Laboratory and Pharmacogenomics Research Services. Transgenomic's two laboratory services divisions utilize these technologies and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit:

Transgenomic Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

                              Transgenomic, Inc.
                          Summary Financial Results
           Unaudited Condensed Consolidated Statements of Operations
                  (dollars in thousands except per share data)

                                                      Three Months Ended
                                                           March 31,
                                                       2009         2008
                                                       ----         ----
     NET SALES                                       $4,989       $6,254
     COST OF GOODS SOLD                               2,176        2,614
                                                      -----        -----
         Gross profit                                 2,813        3,640
         Selling, general and administrative          2,975        2,975
         Research and development                       844          572
                                                        ---          ---
                                                      3,819        3,547
                                                      -----        -----
     INCOME (LOSS) FROM OPERATIONS                   (1,006)          93
         Interest income (expense)                       12           33
         Other, net                                       -           (1)
                                                        ---          ---
                                                         12           32
                                                        ---          ---
     INCOME (LOSS) BEFORE INCOME TAXES                 (994)         125
     INCOME TAX EXPENSE (BENEFIT)                       (41)           3
                                                       ----          ---
     NET INCOME (LOSS)                                 (953)         122
                                                      =====          ===

     BASIC AND DILUTED INCOME (LOSS) PER SHARE       $(0.02)       $0.00
                                                    =======        =====

                                                 ==========   ==========

                                                 ==========   ==========

                            Transgenomic, Inc.
                        Summary Financial Results
           Unaudited Condensed Consolidated Statements of Cash Flows
                          (dollars in thousands)

                                                          Three Months Ended
                                                              March 31,
                                                           2009       2008
                                                           ----       ----
    NET CASH FLOWS USED IN OPERATING ACTIVITIES             299        225

     ACTIVITIES                                            (214)       (85)

     ON CASH                                                (11)       (59)
                                                           ----       ----

    NET CHANGE IN CASH AND CASH EQUIVALENTS                  74         81

                                                          -----      -----

    CASH AND CASH EQUIVALENTS AT END OF PERIOD           $4,845     $5,804
                                                         ======     ======

                              Transgenomic, Inc.
                          Summary Financial Results
                    Condensed Consolidated Balance Sheets
                           (dollars in thousands)

                                                       March 31,  December 31,
                                                         2009        2008
                                                         ----        ----
      Cash and cash equivalents                          $4,845    $4,771
      Accounts receivable (net of allowances for bad
       debts of $356 and $388, respectively)              4,376     5,385
      Inventories                                         4,847     4,775
      Prepaid expenses and other current assets             736       654
                                                            ---       ---
            Total current assets                         14,804    15,585
    PROPERTY AND EQUIPMENT, NET                           1,262     1,198
      Other assets (net of accumulated amortization
       of $437 and $425, respectively)                      741       773
                                                            ---       ---
                                                        $16,807   $17,556
                                                        =======   =======
      Accounts payable                                   $1,243      $905
      Other accrued expenses                              2,653     2,810
      Accrued compensation                                  535       520
                                                            ---       ---
            Total current liabilities                     4,431     4,235
      Other long term liabilities                           118       116
                                                            ---       ---
            Total liabilities                             4,549     4,351
    STOCKHOLDERS' EQUITY                                 12,258    13,205
                                                         ------    ------
                                                        $16,807   $17,556
                                                        =======   =======

SOURCE Transgenomic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Transgenomic, Inc. Forms Scientific Advisory Board
3. Transgenomic, Inc. Reports Third Quarter 2008 Results
4. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... a world leader in rapid infectious disease tests, introduced the Company,s newest product, the ... (Photo: ) Continue Reading ... ... , , bioLytical was invited by the ... INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Biotest Pharmaceuticals Corporation (BPC), a leading manufacturer ... addition of its newest plasma collection center located at ... The 15,200 square foot state-of-the-art facility officially opened its ... the total number of BPC,s plasma collection centers to ... Chief Executive Officer said "We are pleased to become ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):